一视同仁:基于协调员的脆性骨折筛查项目中骨质疏松管理未见性别不平等证据
研究评估加拿大安大略省基于协调员的骨折预防项目能否解决骨质疏松管理中常见的性别差异。纳入≥50岁、筛查时未治疗且6个月内完成随访的脆性骨折患者,排除骨折前一年内已行骨密度检测者。调整后续骨折风险后,随访时药物治疗启动无统计学显著性别差异(p>0.05),高风险女性68.4%、男性66.2%在筛查后6个月内接受治疗。
要点
- 调整骨折风险后,高风险脆性骨折患者随访时药物治疗启动无显著性别差异(p>0.05)。
- 高风险女性68.4%、男性66.2%在筛查后6个月内接受治疗。
- 基于协调员的骨折预防模式在骨折风险调整后未伴随骨质疏松治疗的性别不平等。
核心结论
- 基于需求的分析显示,高风险脆性骨折患者的治疗无性别差异。
- 加拿大安大略省采用的强化协调员骨折预防模式在骨折风险调整后未伴随骨质疏松治疗的性别不平等。
研究设计与样本
- 研究纳入≥50岁、筛查时未接受治疗且筛查后6个月内完成随访的脆性骨折患者。
- 排除当前骨折前一年内已行骨密度检测的患者。
- 所有参与者均通过安大略省骨质疏松策略骨折筛查与预防项目接受骨密度检测,从而提供骨折风险评估数据。
- 主要研究结局为筛查后6个月内随访时启动治疗。
- 性别差异采用Fisher精确检验比较,p<0.05。
主要发现
- 调整后续骨折风险后,参与者在随访时药物治疗启动方面未显示统计学显著的性别差异(p>0.05)。
- 高风险女性68.4%、男性66.2%在筛查后6个月内接受治疗。
关键数值与推荐
- 高风险女性68.4%、男性66.2%在筛查后6个月内接受治疗。
- 调整后续骨折风险后,药物治疗启动的性别差异p>0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We evaluated gender imbalance in osteoporosis management in a provincial coordinator-based fracture prevention program and found no difference by gender in treatment of high-risk fragility fracture patients. This establishes that a systemic approach with interventions for all fragility fracture patients can eliminate the gender inequity that is often observed. INRODUCTION: The purpose of this study was to evaluate an Ontario-based fracture prevention program for its ability to address the well-documented gender imbalance in osteoporosis (OP) management, by incorporating its integrated fracture risk assessments within a needs-based evaluation of equity. METHODS: Fragility fracture patients (≥ 50 years) who were treatment naïve at screening and completed follow-up within 6 months of screening were studied. Patients who underwent bone mineral density (BMD) testing done in the year prior to their current fracture were excluded. All participants had BMD testing conducted through the Ontario OP Strategy Fracture Screening and Prevention program, thus providing us with fracture risk assessment data. Our primary study outcome was treatment initiation at follow-up within 6 months of screening. Gender differences were compared using Fisher's exact test, at p < 0.05. RESULTS: After adjusting for subsequent fracture risk, study participants did not show a statistically significant gender difference in pharmacotherapy initiation at follow-up (p > 0.05). 68.4% of women and 66.2% of men at high risk were treated within 6 months of screening. CONCLUSION: Needs-based analyses show no difference by gender in treatment of high-risk fragility fracture patients. An intensive coordinator-based fracture prevention model adopted in Ontario, Canada was not associated with gender inequity in OP treatment of fragility fracture patients after fracture risk adjustment.
引用
- Ansari H, Beaton DE, Sujic R, et al. Equal treatment: no evidence of gender inequity in osteoporosis management in a coordinator-based fragility fracture screening program. Osteoporos Int. 2017. PMID: 28891035. doi:10.1007/s00198-017-4206-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。